A network meta-analysis of eight randomized trials involving 1,856 patients examined planned mechanical circulatory support during nonemergent complex high-risk indicated percutaneous coronary intervention (CHIP). Percutaneous left ventricular assist devices and intra-aortic balloon pumps reduced reported periprocedural major adverse events compared with standard care, but no support strategy demonstrated a significant reduction in short- or longer-term major adverse cardiovascular events. Evidence for VA-ECMO remained particularly uncertain.
Does Procedural Stability Translate Into Better Outcomes?
Mechanical support can help maintain circulation during a technically demanding coronary intervention. Whether that immediate hemodynamic benefit improves subsequent survival or prevents ischemic events is a separate question. Bujak and colleagues addressed this distinction in a 2026 analysis published in the Journal of the American Heart Association.
The investigators compared percutaneous left ventricular assist devices (pLVADs), intra-aortic balloon pumps (IABP), venoarterial extracorporeal membrane oxygenation (VA-ECMO), and standard care. Their findings challenge routine prophylactic support for every high-risk procedure while leaving open a potential role in carefully selected patients.
Who Was Studied?
The review searched the randomized literature through March 31, 2026. Eligible trials involved nonemergent CHIP, generally in patients with complex coronary anatomy, substantial ventricular dysfunction, or both. Patients with cardiogenic shock at randomization or acute ST-segment elevation myocardial infarction were excluded. These results therefore address planned support in a different setting from rescue support for circulatory collapse.
The eight trials included 727 patients assigned to pLVADs, 512 to IABP, 273 to VA-ECMO, and 344 to standard care. The weighted mean age was 66 years, 17.3% were women, and average left ventricular ejection fraction was 28%. The weighted mean SYNTAX score was 35, reflecting considerable coronary complexity.
Four trials compared a support strategy with standard care, while four compared different support devices. Network meta-analysis combines these direct comparisons with indirect evidence. That expands the comparisons available, but it also depends on the trials being sufficiently comparable.
Key Findings by Support Strategy
| Strategy versus standard care | Periprocedural major adverse events | Longer-term MACE |
|---|---|---|
| pLVAD | RR 0.30; 95% CI 0.10–0.90 | IRR 0.79; 95% CI 0.47–1.35 |
| IABP | RR 0.26; 95% CI 0.07–0.90 | IRR 0.89; 95% CI 0.52–1.54 |
| VA-ECMO | RR 0.45; 95% CI 0.12–1.69 | IRR 1.47; 95% CI 0.64–3.40 |
At approximately 30 days, no individual MCS strategy significantly reduced MACE compared with standard care. Likewise, none demonstrated significant reductions in death, myocardial infarction, stroke, or repeat revascularization at short- or longer-term follow-up. These nonsignificant comparisons do not establish equivalence or prove that benefit is impossible in every subgroup.
Understanding the Procedural Benefit
The favorable procedural signal for pLVADs and IABP concerned study-defined major adverse events, prioritizing composites that included prolonged hypotension, malignant arrhythmia, and cardiopulmonary resuscitation. This outcome should not be confused with the ischemic MACE composite, which emphasized death, myocardial infarction, stroke, and repeat revascularization.
That distinction explains how support could reduce instability during PCI without demonstrating better later clinical outcomes. Long-term prognosis also reflects underlying ventricular disease, residual coronary disease, subsequent medical treatment, and other illnesses. The analysis did not determine which individual patients would gain enough procedural benefit to improve their longer-term course.
Bleeding and Vascular Safety Remain Relevant
The primary network analysis found no statistically significant differences in major bleeding or vascular complications. However, events were uncommon and not uniformly reported, and several confidence intervals were wide. Absence of statistical significance should not be read as proof of equal safety.
IABP showed a nonsignificant trend toward more bleeding of any severity versus standard care (RR 1.53; 95% CI 0.98–2.42). pLVADs showed a nonsignificant trend toward more vascular complications (RR 1.71; 95% CI 0.97–3.01). An exploratory analysis pooling support strategies also suggested increased bleeding. These signals reinforce the importance of considering device-related harm alongside any reduction in procedural instability.
What Perfusion and MCS Teams Can Take From the Study
For multidisciplinary teams, the paper provides an evidence-based framework for discussing why support is being considered: maintaining stability during a difficult intervention, enabling a planned revascularization strategy, or anticipating limited hemodynamic reserve. Those aims should be distinguished from a proven expectation of improved survival.
The findings support selective, individualized planning rather than routine device use based solely on a high-risk label. They do not define a validated selection algorithm, prescribe a cannulation or anticoagulation protocol, or compare rescue strategies in cardiogenic shock. Device preparation, access planning, communication, and escalation readiness remain practical team considerations, rather than interventions proven effective by this analysis.
For related IPA coverage, see the report on combined CPB and Impella 5.5 access. That surgical report concerns a different indication and should not be treated as evidence for prophylactic support during PCI.
Evidence Limits
Only two trials were judged at low risk of bias; six raised some concerns. Definitions of both MACE and procedural adverse events varied. The analysis used aggregate trial data, limiting assessment of patient subgroups and sex- or race-related differences. The relatively small proportion of women also limits generalizability.
Some network comparisons showed disagreement between direct and indirect evidence. VA-ECMO estimates were especially imprecise, and the available data cannot establish either a clear benefit or a clear harm for that strategy. Device platforms and generations were grouped within categories; a class-level estimate cannot be assumed to describe every current device equally well.
The authors discuss additional randomized research as important to resolving these uncertainties. Their overall conclusion is that the evidence does not support routine prophylactic MCS in stable CHIP, while potential benefit in selected patients remains an open question.
Original Article
Bujak K, Laudani C, Giacoppo D, et al. Mechanical Circulatory Support for Complex High-Risk Indicated Percutaneous Coronary Intervention: Network Meta-Analysis of Randomized Trials. Journal of the American Heart Association. 2026;15:e052609. doi:10.1161/JAHA.126.052609.
This independently written IPA educational review summarizes the uploaded open-access publication, distributed under a Creative Commons Attribution–NonCommercial license. The full PDF provides the complete methods and results. The cover is an AI-generated editorial illustration.
